Markers for the identification of late breast cancer recurrence

  title={Markers for the identification of late breast cancer recurrence},
  author={Ivana {\vS}estak and Jack M Cuzick},
  journal={Breast Cancer Research : BCR},
Postmenopausal women with early breast cancer are at an ongoing risk of relapse, even after successful surgery and treatment of the primary tumor. The treatment of breast cancer has changed in the past few years because of the discovery of prognostic and predictive biomarkers that allow individualized breast cancer treatment. However, it is still not clear how to identify women that are at high risk of a late recurrence. Clinical parameters are good prognostic markers for early recurrence, but… 

Predicting Risk of Disease Recurrence

Decision tools and genomic assays assist in stratifying patients into low and high risk so that adjuvant treatment intensity and its potential toxicities can be limited to those who have the most to gain from them.

Risk stratification in early breast cancer in premenopausal and postmenopausal women: integrating genomic assays with clinicopathological features

  • I. Šestak
  • Medicine, Biology
    Current opinion in oncology
  • 2019
Genomic assays have clearly improved prognostication of early oestrogen receptor-positive breast cancer but it is clear that standard clinicopathological parameters are still very important when identifying patient for adjuvant chemotherapy.

High expression of SLC20A1 is less effective for endocrine therapy and predicts late recurrence in ER-positive breast cancer

SLC20A1high can be used as a prognostic biomarker for predicting the efficacy of endocrine therapy and late recurrence for ER+ breast cancer.

Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer

Predictors of early and late distant recurrence might differ according to menopausal status and age, and factors predicting early recurrence were bilateral breast cancer, large tumor size, high lymph node category, high tumor grade, low ER expression and high Ki67 LI.

Differences in Prognostic Factors between Early and Late Recurrence Breast Cancers.

Tumor size, p53 and LN metastasis are the most important risk factors for distance recurrence especially in early recurrence and also between of them, p 53 is significant prognostic factor for early recurrences.

Machine Learning to Discern Interactive Clusters of Risk Factors for Late Recurrence of Metastatic Breast Cancer

A previously developed machine-learning method was applied to retrieve single and interactive clinical and pathological risk factors of 5-, 10- and 15-year metastases of metastatic breast cancer and found that, with lower alpha values (low interactivity score), the prevalence of variables with an independent influence on long-term metastasis was higher.

Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer

Predictors for prognosis after relapse differed between patients with the early and late distant recurrence, and it is important to establish whether metastatic tumors are endocrine-resistant in ER-positive, HER2-negative recurrent breast cancer.

Prediction of late recurrence in patients with breast cancer: elevated neutrophil to lymphocyte ratio (NLR) at 5 years after diagnosis and late recurrence

Elevated NLR is found as an independent prognostic factor for late recurrence and could be utilized as a reliable, easily accessible, and cost-effective test.

Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor

It is demonstrated that not only host defense immunity, but also pro-cancerous immune cells and immune cell cytolytic activity in primary BC was associated with late recurrence, compared with all recurrence groups in pre-ranked GSEA.

The Progressive Journey from Ductal Carcinoma in situ into Invasive Breast Cancer: An Extensive Systematic Literature Review on Biomarkers

Research in breast cancer biomarkers related to DCIS and IBC is enlightened, and little is known/or there is still a lot to know about molecular biomarkers (BM) that may help to determine the likelihood that DCIS identified on diagnostic biopsy would remain contained in situ or become invasive.



Biologic markers determine both the risk and the timing of recurrence in breast cancer

Using pooled data from four publicly available data sets for node-negative tumors annotated with gene expression and outcome data, four prognostic gene signatures were evaluated: two proliferation-based and two immune function-based, which predicted early but not late metastatic risk in Tneg and HER2pos cases.

Breast Cancer Index Identifies Early-Stage Estrogen Receptor–Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence

The prognostic sustainability of BCI to assess early- and late-distant recurrence risk at diagnosis has clinical use for decisions of chemotherapy at diagnosis and for decisions for extended adjuvant endocrine therapy beyond five years.

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer

None of the IHC4 markers provided statistically significant prognostic information in years 5 to 10, except for nodal status and tumor size, which may help select patients who could benefit most from hormonal therapy beyond 5 years of treatment.

Annual hazard rates of recurrence for breast cancer after primary therapy.

  • T. SaphnerD. TormeyR. Gray
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
Patients 5 years postsurgery for breast cancer appear to have a very slowly decreasing hazard of recurrence, and this group of patients may be well suited for trials evaluating cytostatic drugs or differentiating agents.

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer and could be used as a continuous function to predict distant recurrent in individual patients.

Abstract S1-9: Comparative Performance of Breast Cancer Index (BCI) vs. Oncotype Dx and IHC4 in the Prediction of Late Recurrence in Hormonal Receptor-Positive Lymph Node-Negative Breast Cancer Patients: A TransATAC Study

This is the first large-scale clinical study to compare several multi-gene signatures for their prognostic strength to quantify late residual risk of recurrence after endocrine therapy.

The tumor macroenvironment and systemic regulation of breast cancer progression.

The systemic, or "macroenvironmental", contribution to tumor initiation and progression and what is known about how a pro-tumorigenic systemic environment is established are addressed.

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

A gene expression signature predicting the likelihood of distant recurrence in patients with estrogen receptor–positive, HER2-negative breast cancer treated with adjuvant endocrine therapy is developed and validated.

A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype

The findings suggest that an EMT-related gene signature in the tumor epithelium is related to both stromal activation and escape from disease dormancy in breast cancer.